According to a new market report published by Lucintel, the future of the hospital acquired disease testing market looks promising with opportunities in hospitals and intensive care units (ICUS). The global hospital acquired disease testing market is expected to grow with a CAGR of 15% from 2020 to 2025. The major drivers for this market are increasing prevalence of hospital acquired infections, growing number of drug-resistant pathogens, and rising awareness among people of hospital acquired diseases.
To download report brochure, please go to https://www.lucintel.com/hospital-acquired-disease-testing-market.aspx and click "download brochure" tab from the menu
Hospital acquired disease testing is used by healthcare professionals, especially by clinical laboratory technicians, for the diagnosis of nosocomial infection. In this market, urinary tract infection, surgical site infection, pneumonia stents, blood stream infection, and methicillin-resistant staphylococcus aureus are the major test type segments. Lucintel forecasts that urinary tract infection will remain the largest test type segment over the forecast period due to high prevalence of hospital acquired infections and increasingly popular techniques that are being used for preventing, diagnosing, & treating the hospital-associated infections, such as polymerise chain reaction (PCR), solid-phase hybridization, and microarrays.
Within this market, hospitals and intensive care units (ICUs) will remain the largest end user segment over the forecast period.
North America will remain the largest region over the forecast period due to increase in geriatric population and robust healthcare infrastructure in this region.
Diatherix, Roche, Cantel Medical, Qiagen, Cephid, and bioMeriux are among the major suppliers in the global hospital acquired disease testing market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global hospital acquired disease testing market by test type, end user, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Hospital Acquired Disease Testing Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global hospital acquired disease testing market by test type, end user, and region as follows:
By Test Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals and Intensive Care Units (ICUs)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes and Maternity Centers
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
Spain
Italy
France
This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.